These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 28351285)
1. Heparanase overexpression down-regulates syndecan-1 expression in a gallbladder carcinoma cell line. Jin H; Zhou S; Yang S; Cao HM J Int Med Res; 2017 Apr; 45(2):662-672. PubMed ID: 28351285 [TBL] [Abstract][Full Text] [Related]
2. Gene silencing of heparanase results in suppression of invasion and migration of gallbladder carcinoma cells. Jin H; Cui M Biosci Biotechnol Biochem; 2018 Jul; 82(7):1116-1122. PubMed ID: 29598788 [TBL] [Abstract][Full Text] [Related]
3. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857 [TBL] [Abstract][Full Text] [Related]
4. [mRNA expression of syndecan-1 and heparanase in relation to tumor progression and prognosis of gastric carcinoma]. Ru GQ; Zhao ZS; Tang QL; Xu WJ Zhonghua Wai Ke Za Zhi; 2006 Aug; 44(15):1062-4. PubMed ID: 17074248 [TBL] [Abstract][Full Text] [Related]
5. Heparanase regulates levels of syndecan-1 in the nucleus. Chen L; Sanderson RD PLoS One; 2009; 4(3):e4947. PubMed ID: 19305494 [TBL] [Abstract][Full Text] [Related]
6. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway. Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511 [TBL] [Abstract][Full Text] [Related]
8. Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides. Chang XZ; Wang ZM; Yu JM; Tian FG; Jin W; Zhang Y; Yu J; Li LF; Liu XF; Li ZW; Shao ZM Clin Exp Metastasis; 2007; 24(1):25-38. PubMed ID: 17260103 [TBL] [Abstract][Full Text] [Related]
9. High glucose-induced intestinal epithelial barrier damage is aggravated by syndecan-1 destruction and heparanase overexpression. Qing Q; Zhang S; Chen Y; Li R; Mao H; Chen Q J Cell Mol Med; 2015 Jun; 19(6):1366-74. PubMed ID: 25702768 [TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of silencing heparanase expression with antisense oligodeoxynucleotide on invasive capability of human esophageal squamous cancer cell line TE-13]. Zhu H; Wang SJ; Wang SX; Meng XL; Wang YJ Ai Zheng; 2005 Dec; 24(12):1431-5. PubMed ID: 16351787 [TBL] [Abstract][Full Text] [Related]
12. Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and α-actinin. Shteingauz A; Ilan N; Vlodavsky I Cell Mol Life Sci; 2014 Nov; 71(22):4457-70. PubMed ID: 24788042 [TBL] [Abstract][Full Text] [Related]
13. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152 [TBL] [Abstract][Full Text] [Related]
14. Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Zhou L; He XD; Yu JC; Zhou RL; Xiong FX; Qu Q; Rui JA Hepatogastroenterology; 2010; 57(98):207-11. PubMed ID: 20583413 [TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of syndecan-1 mRNA and HPA-1 mRNA in colorectal cancer detected with real-time fluorescent quantitative polymerase chain reaction. Wang H; Si JL; Zhang XZ; Qi YQ; Niu ZY; Zhou CH Chin J Cancer; 2010 Mar; 29(3):288-93. PubMed ID: 20193112 [TBL] [Abstract][Full Text] [Related]
16. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. Purushothaman A; Hurst DR; Pisano C; Mizumoto S; Sugahara K; Sanderson RD J Biol Chem; 2011 Sep; 286(35):30377-30383. PubMed ID: 21757697 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of heparanase inhibitors in cancer therapy. Heyman B; Yang Y Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132 [TBL] [Abstract][Full Text] [Related]
18. [Effects of heparanase inhibition by RNA interference on proliferation, invasiveness and apoptosis of lung cancer cells]. Zhang QF; Huang Q; Liu N; Jiang LL; Qiu XS; Wang EH Zhonghua Bing Li Xue Za Zhi; 2008 Dec; 37(12):826-30. PubMed ID: 19159529 [TBL] [Abstract][Full Text] [Related]
19. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281 [TBL] [Abstract][Full Text] [Related]